Probiotic use in clinical practice: what are the risks?

被引:468
作者
Boyle, Robert J.
Robins-Browne, Roy M.
Tang, Mimi L. K.
机构
[1] Royal Childrens Hosp, Dept Immunol, Murdoch Childrens Res Inst, Asthma Allergy & Immune Disorders Grp, Parkville, Vic 3052, Australia
[2] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia
关键词
probiotics; sepsis; Lactobacillus; Saccharomyces;
D O I
10.1093/ajcn/83.6.1256
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Probiotics have been advocated for the prevention and treatment of a wide range of diseases, and there is strong evidence for their efficacy in some clinical scenarios. Probiotics are now widely used in many countries by consumers and in clinical practice. Given the increasingly widespread use of probiotics, a thorough understanding of their risks and benefits is imperative. In this article we review the safety of probiotics and discuss areas of uncertainty regarding their use. Although probiotics have an excellent overall safety record, they should be used with caution in certain patient groups-particularly neonates born prematurely or with immune deficiency. Because of the paucity of information regarding the mechanisms through which probiotics act, appropriate administrative regimens, and probiotic interactions, further investigation is needed in these areas. Finally, note that the properties of different probiotic species vary and can be strain-specific. Therefore, the effects of one probiotic strain should not be generalized to others without confirmation in separate studies. Careful consideration should be given to these issues before patients are advised to use probiotic supplements in clinical practice.
引用
收藏
页码:1256 / 1264
页数:9
相关论文
共 74 条
[1]  
Alander M, 1999, APPL ENVIRON MICROB, V65, P351
[2]  
ALLEN SJ, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003048.PUB2
[3]  
[Anonymous], 2002, GUIDELINES EVALUATIO
[4]   Good adhesion properties of probiotics: a potential risk for bacteremia? [J].
Apostolou, E ;
Kirjavainen, PV ;
Saxelin, M ;
Rautelin, H ;
Valtonen, V ;
Salminen, SJ ;
Ouwehand, AC .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2001, 31 (01) :35-39
[5]   Host-bacterial mutualism in the human intestine [J].
Bäckhed, F ;
Ley, RE ;
Sonnenburg, JL ;
Peterson, DA ;
Gordon, JI .
SCIENCE, 2005, 307 (5717) :1915-1920
[6]   Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii [J].
Bassetti, S ;
Frei, R ;
Zimmerli, W .
AMERICAN JOURNAL OF MEDICINE, 1998, 105 (01) :71-72
[7]  
Benno Y., 1996, NUTR TODAY, V31, p9S
[8]   Safety of probiotics that contain lactobacilli or bifidobacteria [J].
Borriello, SP ;
Hammes, WP ;
Holzapfel, W ;
Marteau, P ;
Schrezenmeir, J ;
Vaara, M ;
Valtonen, V .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (06) :775-780
[9]   Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism [J].
Cassone, M ;
Serra, P ;
Mondello, F ;
Girolamo, A ;
Scafetti, S ;
Pistella, E ;
Venditti, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (11) :5340-5343
[10]   Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii [J].
Cesaro, S ;
Chinello, P ;
Rossi, L ;
Zanesco, L .
SUPPORTIVE CARE IN CANCER, 2000, 8 (06) :504-505